ABBV-932
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) drugs
Cariprazine (QLM1016). Compare all 2 Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Bipolar Depression: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ABBV-932: this drug | Stage not on record | Small molecule | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lurasidone | Approved | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (QLM1016) | Phase 3(overall) | Small molecule | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| D-Cycloserine / Lurasidone (NRX-101) | Phase 3 | Small molecule | NMDA receptor (glycine site) + dopamine/5-HT receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ABBV-932 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.